Shares of Evoke Pharma Inc. (NASDAQ:EVOK) shot up 12.1% during trading on Friday . The company traded as high as $8.00 and last traded at $7.87, with a volume of 103,660 shares. The stock had previously closed at $7.02.

A number of research firms have commented on EVOK. Zacks Investment Research upgraded Evoke Pharma from a “hold” rating to a “buy” rating and set a $5.50 target price on the stock in a research report on Tuesday, May 3rd. FBR & Co restated a “buy” rating on shares of Evoke Pharma in a research report on Saturday, May 14th. Brean Capital restated a “buy” rating on shares of Evoke Pharma in a research report on Friday. Northland Securities assumed coverage on Evoke Pharma in a research report on Wednesday, March 16th. They issued an “outperform” rating and a $16.00 price objective on the stock. Finally, Rodman & Renshaw restated a “buy” rating on shares of Evoke Pharma in a research report on Thursday, May 12th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Evoke Pharma presently has a consensus rating of “Buy” and a consensus price target of $17.47.

The stock’s 50 day moving average is $5.95 and its 200 day moving average is $4.52. The company’s market cap is $59.30 million.

Evoke Pharma (NASDAQ:EVOK) last posted its earnings results on Wednesday, May 11th. The specialty pharmaceutical company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.41) by $0.04. Analysts anticipate that Evoke Pharma Inc. will post ($1.36) EPS for the current fiscal year.

In other news, major shareholder Parters Vii L. P. Domain sold 344,120 shares of Evoke Pharma stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $4.70, for a total transaction of $1,617,364.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Parters Vii L. P. Domain sold 5,095 shares of Evoke Pharma stock in a transaction on Wednesday, April 27th. The shares were sold at an average price of $5.07, for a total value of $25,831.65. The disclosure for this sale can be found here.

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.